https://www.zaobao.com.sg/realtime/world/story20210506-1144682
美国莫德纳公司周三（5月5日）宣布，一项小型临床试验的初步数据显示，莫德纳追加剂可改善人们对主要冠病变种病毒的免疫反应。
莫德纳总裁邦塞尔（Stephane Bancel）说：“我们对这些新数据感到鼓舞，我们的追加剂策略应该能够防御这些新发现的变种，对此我们充满信心。”
在临床试验中，40名参与者在接种两剂疫苗后的六至八个月接受了中和抗体水平的测试。参与者之后接种了第三剂莫德纳疫苗，或用于对抗特定变种病毒的追加剂，结果发现这两种疫苗提高了对南非和巴西变种病毒的抗体水平。
PS
Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern
Single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two variants of concern (B.1.351, P.1) in previously vaccinated clinical trial participants
Booster dose of mRNA-1273.351, a strain-matched candidate, achieved higher titers against B.1.351 than a booster dose of mRNA-1273
mRNA-1273.351 and mRNA-1273 booster doses were generally well tolerated
Evaluation of a multivalent vaccine booster candidate, mRNA-1273.211, is ongoing; data expected shortly